BioXcel's Teva sale prices the assets, not the common stock

Summary: U.S. short Watchlist. BioXcel Therapeutics (Nasdaq: BTAI) printed $0.1814 in the latest available finance-feed context at 2026-08-29 00:15:00 UTC, down 74.76% on 58.56 million shares. On Aug. 27, the company filed Chapter 11, disclosed up to $19 million of new-money DIP financing plus $58.25 million of roll-up loans, and signed a stalking-horse asset purchase agreement with Teva for $57.5 million of upfront cash plus contingent milestones. The sale process creates a real path for the common stock to lose most of its residual value, but the stock has already collapsed, the price feeds disagree on the regular-session high, and secondary borrow data showed zero shares available on Aug. 28. This is a reference-only short thesis, not an executable trade or personalized financial advice.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	BioXcel Therapeutics (BTAI)	Short	A non-zero common quote sits against a Chapter 11 sale, DIP roll-up, large prepetition liabilities, and a deeply negative June stockholders' deficit	Aug. 27 to Aug. 28 official filings	First-day DIP orders, sale procedures, auction, closing, and Oct. 30 outside date	3.31 million shares short, 10.78% of float; secondary borrow showed 0 shares available	Watchlist; reject for current execution	Quote available, but locate, borrow, recall, spread, depth, and exit liquidity are not verified	A higher bid, court-approved common recovery, milestone value, or a squeeze overwhelms the short
2	KALA BIO (KALA)	Short	Nasdaq deficiency and a June cash balance of only $0.229 million conflict with a residual common quote and a new AI-infrastructure pivot	Aug. 27 8-K and June 30 10-Q	Listing appeal, financing, and next balance-sheet filing	Secondary borrow fee about 8.84%, 40,000 shares shown available; only 1.50% of shares short in the latest cited FINRA snapshot	Reject for current execution	Thin quote, post-split history, and broker-level execution data missing	Appeal, financing, or a strategic announcement causes a sharp squeeze
3	SuperX AI Technology (SUPX)	Short	An expensive AI-server narrative is ahead of the latest audited operating base, but orders include a disclosed advance payment	Aug. 25 and Aug. 28 company disclosures	B300 delivery, acceptance, collection, and the next financial filing	Short interest about 2.06% of public float; secondary borrow fee about 15.13% with shares shown available	Reject for current execution	More borrow capacity, but current 2026 balance sheet, depth, and exit evidence are incomplete	The $38.8 million order, 20% advance, and new 128-cluster order convert into cash and accepted revenue

Candidate operating facts use the BTAI SEC 8-K, KALA SEC 8-K, and SUPX SEC 6-K. Candidate market and borrow context is linked in KALA price history, SUPX price history, KALA borrow data, and SUPX borrow data.

Selected opportunity: BioXcel Therapeutics, Inc. (BTAI), Nasdaq Capital Market common stock.

Why this one now: BTAI has the freshest primary evidence of a capital-structure event that can adjudicate common value. The Chapter 11 petition, DIP financing, Teva APA, and sale process are observable. That evidence is more concrete than KALA's listing problem and less counterbalanced by new operating cash evidence than SUPX's customer advance. The execution gates still fail.

What should surprise the reader: The $57.5 million Teva number is not a common-equity recovery. It is consideration in a court-supervised asset sale with a DIP stack, prepetition claims, assumed liabilities, conditional milestones, and a higher-bid process ahead of any distribution to common.

Why This Is the Best Opportunity Right Now

BioXcel and its subsidiaries filed voluntary Chapter 11 petitions in Delaware on Aug. 27, 2026. The same filing disclosed a stalking-horse APA with Teva for substantially all assets. The consideration includes $57.5 million of upfront cash, up to $67.5 million of development milestones linked to the pending IGALMI supplemental approval for at-home use, and up to $20 million of commercial milestones tied to post-close sales. Teva would assume specified liabilities. The transaction remains subject to higher or better bids, bankruptcy-court approval, and closing conditions, with an outside date of Oct. 30, 2026. These are facts from the company's Aug. 27 8-K, not a forecast of closing or recovery. BioXcel Aug. 27 8-K

The debtor also disclosed up to $19 million of new-money DIP financing, in two proposed $9.5 million draws, alongside $58.25 million of roll-up loans that convert part of prepetition obligations into DIP claims. New money is liquidity. Roll-up is a claim transformation, not fresh cash. Neither amount can be subtracted from a stock quote to produce a common value without the final DIP order, collateral and priority terms, claims schedule, sale expenses, assumed liabilities, and post-close distribution waterfall.

The June 30 10-Q shows why the common-equity question is asymmetric. BioXcel reported $12.841 million of cash and cash equivalents, $0.960 million of restricted cash, $137.149 million of current liabilities, $7.110 million of derivative liabilities, and $144.259 million of total liabilities. Stockholders' deficit was $115.460 million. First-half operating cash use was $17.907 million, while first-half IGALMI product revenue was only $0.388 million. Common shares outstanding were 31.305 million at quarter-end. The 10-Q also warned that available cash was insufficient to support current operations and debt for at least one year absent a strategic transaction or financing. BioXcel June 30 10-Q

The market may be right that a court-supervised sale preserves an operating asset and creates milestone optionality. It may also be right that the quote represents a distressed option rather than a conventional valuation. The short thesis is narrower: the quote can still be wrong about how much of the estate reaches common after the senior and process claims are fixed. Because the postpetition ledger and court orders are not yet verified, this remains an underwriting question rather than a trade authorization.

Why This Can Move More Than 5% Soon

The stock already fell more than 5%, but the relevant question is whether another material repricing can occur during the Aug. 31 to Oct. 30 sale window. Several state changes can move the common quote sharply in either direction:

An interim or final DIP order can establish the funding, roll-up, collateral, and priority structure that sits ahead of common.
Sale procedures and a bid deadline can turn the Teva APA from a headline into a competitive process, or expose a lack of competing interest.
A higher or better bid can increase estate value and create a squeeze even if common recovery remains uncertain.
A court-approved sale, plan, or settlement can reveal how assumed liabilities, claims, milestones, and distributions interact.
A short recall, buy-in, halt, or corporate action can dominate the operating thesis because BTAI traded tens of millions of shares through a distressed gap.

The move is therefore event-driven and path-dependent. A short taken after a 74.76% fall is not protected by the fact that the original thesis was directionally correct.

10/5 Asymmetry Gate

The holding window is Aug. 31 through Oct. 30, 2026, centered on first-day orders, sale procedures, a possible auction, and the outside date in the APA. The only observed price is a reference mark. No verified executable entry is available.

Test	Calculation or evidence	Result
Reference price	$0.1814, latest available finance-feed context at 2026-08-29 00:15:00 UTC	Reference only
Favorable base move	Short from $0.1814 to $0.08: (0.1814 - 0.08) / 0.1814	+55.90% before costs
Credible adverse move	Short from $0.1814 to $0.60: (0.60 - 0.1814) / 0.1814	-230.76% before costs
Gross favorable-to-adverse ratio	55.90% / 230.76%	0.24:1, below 2:1
After-cost value	Borrow duration, actual fee, slippage, locate, recall, spread, depth, and exit liquidity are not verified	Cannot compute responsibly
Measurement basis	Verified entry or reference-only	Reference-only
Classification	10/5 downside and execution gates	Watchlist; reject for current trade

The base decline is comfortably above 10%, but the bottom case is not bounded near 5%. The 10/5 hurdle fails on adverse risk, gross ratio, and execution. Bankruptcy gaps and halts can bypass a stop order, so a nominal percentage stop would not repair the asymmetry.

What Should Surprise the Reader

The company can sell substantially all assets for a number larger than the provider's current market-cap context while common shareholders still receive little or nothing. That is not a paradox. The sale amount is an estate consideration with assumed liabilities, milestone conditions, transaction costs, DIP claims, prepetition claims, and a court process. A provider market cap is a price-times-share arithmetic, not an estimate of residual value after those claims.

The other surprise is that a common stock can be most dangerous to short after the operating thesis appears obvious. BTAI's 74.76% one-day decline creates the possibility of covering, recall, halt, or higher-bid reflexivity. The court process can reduce common value and still make the short expression untradeable.

The Setup

BioXcel developed IGALMI, a sublingual dexmedetomidine product for acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. The June 10-Q showed only $388,000 of first-half IGALMI product revenue against continuing cash needs. The Aug. 27 filing moved the main valuation question from commercial adoption to estate priority and sale execution.

The Teva APA is a stalking-horse reference in a competitive process, not proof that the transaction will close and not a floor for the common stock. The filing states that higher or better bids can be considered. Development and commercial milestones are contingent; they are not current cash. The proposed DIP roll-up is a claim state; it is not a new-money runway extension of $58.25 million.

The load-bearing short assumption is that the final senior-claim and sale-cost bridge consumes most residual common value. That assumption is plausible from the June deficit and liability data, but it is not proven until the court orders and postpetition claim ledger are available.

The Market Price

Observation	Value	Timestamp / session	Source and limitation
Latest finance-feed price	$0.1814	2026-08-29 00:15:00 UTC; context feed	Yahoo Finance BTAI quote; latest available feed observation
Finance-feed change	-$0.5374, -74.76349%	Same observation	Yahoo Finance BTAI quote; provider context
Finance-feed open / high / low	$0.2122 / $0.6078 / $0.1570	Same observation	Yahoo Finance BTAI quote; high conflicts with the regular-session history below
Finance-feed volume	58,562,829 shares	Same observation	Yahoo Finance BTAI quote; venue and volume quality unverified
Provider market-cap context	$5,496,420	Same observation	Yahoo Finance BTAI quote; not a reconciled postpetition equity value
Regular-session close / high / low	$0.1814 / $0.2299 / $0.1569	Aug. 28, 2026 regular session	ChartExchange BTAI history; differs from the finance-feed high
After-hours snapshot	$0.1790	Aug. 28, 2026 at 4:59:30 p.m. EDT	ChartExchange BTAI history; not an executable quote

The high mismatch is material. I use $0.1814 only as the latest context mark because both cited histories show that close, but I do not treat either source as a verified bid, ask, spread, depth, or exit-liquidity snapshot. The June 30 share count of 31.305 million times $0.1814 gives about $5.68 million of price-only arithmetic. That calculation is not current market capitalization and does not resolve postpetition claims or the denominator.

The Mispricing

The quote may still contain residual common optionality from the Teva sale, IGALMI milestones, a higher bid, or a court-approved restructuring. It also may be assigning too much value to those paths because the balance sheet entered Chapter 11 with a $115.460 million stockholders' deficit and $144.259 million of liabilities.

The key distinction is between estate value and common value:

The Teva upfront payment is consideration for assets and specified liabilities, not a payment to common holders.
The $19 million new-money DIP amount can preserve the process, but it adds senior financing obligations.
The $58.25 million roll-up changes claim priority and treatment; it does not create $58.25 million of distributable cash.
The development and commercial milestones are contingent and arrive, if at all, after future events.
Common recovery depends on the court-approved claims and distribution bridge, not on the headline APA amount.

No enterprise value or residual equity value is computed here. The current balance sheet is prepetition, the provider market capitalization is not reconciled to a current denominator, and the postpetition claims, DIP order, sale expenses, assumed liabilities, and plan treatment are not fully available in an auditable single timestamp.

The Positioning

The latest FINRA-sourced short-interest calendar cited by Benzinga showed 3,314,382 shares short, or 10.78% of a 30,740,216-share float, at the Aug. 14 settlement date, with 4.16 days to cover. The prior July 31 observation showed 4,214,920 shares, or 13.90% of float, and 9.68 days to cover. These are settlement-date observations, not live short positions. Benzinga BTAI short-interest calendar

A secondary borrow tracker showed a borrow fee near 6.83% and 3,000 shares available in one current snapshot, while its Aug. 28 history showed zero shares available. Another secondary source showed the recent fee moving between roughly 6.5% and 8.1%. These are indicative data, not a broker-level locate or a guarantee that shares can be borrowed at the quoted rate. ShortInterestTracker BTAI

Positioning is therefore tense but incomplete. A 10.78% short-float figure can support a squeeze, but it does not tell us who can recall shares, how much of the short is stale, whether the float has changed after the petition, or whether a locate is available now. I score positioning 3/5, not 5/5, because direct borrow, recall, utilization, live order-book, and fund-flow evidence is missing.

The Catalyst

Catalyst	State and timing	Observable test	Directional implication
Chapter 11 first-day process	Petition filed Aug. 27, 2026	Interim and final DIP orders, approved borrowing, actual draw, collateral and priority terms	A senior and funded process can pressure residual common value; rejection or delay can create a squeeze
Teva stalking-horse APA	Signed Aug. 27; outside date Oct. 30	Sale motion, bidding procedures, bid deadline, auction state, court approval, and closing conditions	No competing bid can reduce optionality; a higher or better bid can reprice the stock upward
Sale consideration	$57.5 million upfront plus contingent milestones	Actual cash received, liabilities assumed, fees, milestones, and post-close estate accounting	Proceeds are only relevant to common after the claim and cost bridge
Common recovery and plan	Not yet verified	Claims schedule, disclosure statement, plan, settlement, distribution and cancellation treatment	A documented common recovery invalidates the short thesis; no recovery is not assumed before the court record
Securities class-action settlement	Estimated $9.750 million, insurer-funded, pending final approval	Sept. 2, 2026 final-approval hearing and any cash-release terms	Settlement state can alter claims and timing, but it is not a common-equity distribution

The cheapest falsification sequence is the interim and final DIP order, the sale and bidding-procedure orders, the claims schedule, the actual closing and cash ledger, then the plan or distribution disclosure. A headline about the APA is not a substitute for that sequence.

The Payoff

The payoff map is deliberately price-only because an auditable postpetition balance sheet and executable entry are unavailable.

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	35%	$0.03	+83.46% short return before costs	By Oct. 30, 2026	DIP and sale process fix senior claims, no credible higher bid emerges, and common recovery becomes remote	Medium
Base Case	45%	$0.08	+55.90% short return before costs	By Oct. 30, 2026	Teva process continues, the estate value is absorbed by claims and costs, and the quote converges lower without a verified common recovery	Medium
Bottom Case	20%	$0.60	-230.76% short return before costs	During the sale window	Higher bid, milestone or court surprise, borrow recall, covering, halt reopening, or residual common optionality drives a squeeze	Medium
Invalidation	n/a	Court-approved documents show a material common recovery or another fact breaks the claim bridge	Exit or remove the thesis; do not wait for a price stop	As observed	Common recovery, higher bid, or materially different DIP and claim treatment is documented	High when filed

Probability-weighted expected value: Price-only target = (0.35 x $0.03) + (0.45 x $0.08) + (0.20 x $0.60) = $0.1665. Against the $0.1814 reference, that is an 8.21% expected short return before borrow, spread, slippage, funding, recall, and settlement costs. After-cost EV cannot be computed responsibly because the entry and short-side execution states are unverified.

Current market level and timestamp: $0.1814 finance-feed context, 2026-08-29 00:15:00 UTC.

Primary instrument: BTAI common stock only, if every future gate is independently verified.

10/5 favorable base move: 55.90% decline from the reference-only mark.

10/5 credible adverse move: 230.76% underlying rise to the bottom-case level.

10/5 measurement basis: Reference-only, not verified entry.

10/5 status: Watchlist for research; Reject for current execution.

Confidence: Medium on the Aug. 27 to Aug. 28 filings and price context. Low to Medium on residual common recovery, current claims, borrow, recall terms, venue quality, and the probability map.

The Kill Shot

The strongest counterparty argument is that bankruptcy is not automatically a zero for common. Teva may want IGALMI and the development program for strategic reasons. The court process can attract a higher bid. Contingent milestones can become valuable if the at-home-use application succeeds. DIP liquidity can keep the operating asset alive long enough to create more estate value. A market that discounts only the June balance sheet could be wrong if the APA's total consideration, assumed liabilities, and bidding process deliver more than expected.

The short also faces a mechanical problem. The stock has already repriced from the prior close by more than 70%, so a correct fundamental thesis may be crowded into an unavailable borrow. A recall or buy-in can force a loss before the court process clarifies common recovery. The load-bearing assumption is not “bankruptcy means zero.” It is that the final senior-claim, process-cost, and sale bridge leaves little common value while borrow remains available long enough to realize it. That assumption is currently unverified.

What Could Go Wrong

Teva's strategic interest or a competing bidder produces a higher or better offer.
Development or commercial milestones become more valuable than the market expects.
The court approves a DIP and sale structure that leaves a material residual for common.
A court delay, filing, hearing, or plan disclosure creates a sharp upward repricing before a short can exit.
Borrow is recalled, bought in, repriced, or unavailable after entry; the secondary tracker is not a broker locate.
A halt, gap, reverse split, settlement adjustment, or corporate action bypasses an intended stop.
The latest quote is not executable, and the 58.56 million-share volume includes prints that do not represent available exit liquidity.
Postpetition claims, derivative liabilities, litigation, taxes, assumed liabilities, or sale expenses are larger or structured differently than the June filing suggests.
IGALMI or the retained program generates operating evidence that attracts a new financing or strategic partner.
A short can lose more than the planned percentage even if the estate ultimately produces no common recovery.

What Would Prove This Wrong

The thesis is invalidated if a filed court order, plan, settlement, or closing ledger documents a material common recovery, or if a higher or better bid makes the residual claim economically meaningful. A verified Teva closing with transparent cash received, assumed liabilities, senior claims, and distribution treatment can replace the current price-only map. Strong IGALMI commercialization alone would not settle common recovery, but it would weaken the assumption that the estate has no strategic optionality.

Execution is independently invalidated if a broker cannot locate and borrow the shares, if recall or buy-in terms are unacceptable, if a fresh regular-session quote is near a halt or session low, or if spread, depth, venue, volume quality, and exit liquidity cannot be verified. Those are no-trade conditions even if the bankruptcy thesis remains directionally plausible.

Risk Audit

Risk	Current evidence	Control
Capital stack	$144.259 million of June liabilities, $115.460 million stockholders' deficit, proposed $19 million new-money DIP and $58.25 million roll-up	Rebuild the claim ladder from court orders, claims schedule, sale costs, assumed liabilities, and distribution documents
Sale and auction	Teva APA has $57.5 million upfront consideration and contingent milestones; higher or better bids remain possible	Do not treat the APA as a common-value floor; monitor bidding procedures, auction, approval, and closing
Borrow and recall	Secondary snapshot showed 0 shares available and a 6.83% fee; no broker locate	No entry without a current broker-level locate, borrow fee, recall and buy-in terms
Market structure	Finance-feed high $0.6078 conflicts with the regular-session history high $0.2299; bid, ask, spread and depth are missing	Require one fresh regular-session venue and top-of-book audit; do not short a halt or session low
Gap and halt	The stock fell 74.76% with 58.56 million shares in the finance context	No reliance on a 5% stop; cap exposure only after maximum loss and exit liquidity are observable
Common denominator	June 30 common count was 31.305 million, but postpetition issuance and settlement are unknown	Verify current shares, corporate actions, claims, and any plan or restructuring denominator
Operations and milestones	H1 IGALMI revenue was $0.388 million; milestone value is contingent	Track actual product, regulatory, milestone and cash evidence, not the headline amount
Legal and settlement	Securities settlement was described as pending final approval; derivative and SEC matters remain disclosed	Read the final court and settlement records before changing the thesis

Best Trade Strategy

This is a Watchlist research expression, not an executable trade.

Instrument: BTAI common stock only. No options, leverage, margin, or market order is supported by the current evidence.
Entry state: entry.price = null. The $0.1814 reference is not an executable entry. execution.can_execute = false.
Required market gates: fresh regular-session quote, venue, bid, ask, spread, depth, volume quality, and exit liquidity. The price feed conflict must be resolved before any implementation.
Required short gates: broker-level locate, borrow fee, utilization, recall and buy-in terms, settlement state, and current short-side availability. The secondary borrow snapshot is not sufficient.
Required fundamental gates: interim and final DIP orders, sale and bidding procedures, current claims and assumed liabilities, actual cash received, milestone treatment, plan or distribution state, and current common denominator.
Conditional targets: $0.03 top, $0.08 base, and $0.60 bottom are scenario levels only. They are not guaranteed exits and do not create a price floor or an execution instruction.
Horizon: Aug. 31 through Oct. 30, 2026, subject to earlier invalidation or a material court, sale, borrow, or trading-status change.
Do not trade: Do not short after a one-day collapse, through a halt, against an unverified locate, or solely because the Teva consideration exceeds the provider market-cap context. Do not use options or leverage without a separately verified live chain, spread, liquidity, assignment, and maximum-loss analysis.

Sources

BioXcel Aug. 27, 2026 SEC Form 8-K - Chapter 11 petition, DIP terms, Teva APA, consideration, milestones, sale process, and settlement disclosure.
BioXcel June 30, 2026 Form 10-Q - cash, restricted cash, liabilities, deficit, operating cash use, IGALMI revenue, common shares, and liquidity warning.
BioXcel asset-sale release - company summary of the Teva APA dated Aug. 27, 2026.
Yahoo Finance BTAI quote - latest available finance-feed context at 2026-08-29 00:15:00 UTC.
ChartExchange BTAI history - Aug. 28 regular-session and after-hours price history; high differs from the finance-feed field.
Benzinga BTAI short-interest calendar - FINRA-sourced settlement-date short-interest and days-to-cover context.
ShortInterestTracker BTAI - secondary indicative borrow fee and availability context; not a broker locate.
KALA Aug. 27, 2026 SEC Form 8-K - candidate Nasdaq bid-price deficiency and appeal state.
KALA June 30, 2026 Form 10-Q - candidate cash, operating cash use, preferred conversion, liabilities, and denominator.
KALA price history - candidate Aug. 28 market context.
KALA borrow context - candidate indicative borrow and short-interest context.
SUPX Aug. 25, 2026 SEC Form 6-K and exhibit - candidate B300 order, $38.8 million value, delivery window, and 20% advance.
SuperX company news - candidate Aug. 28 128-cluster order announcement.
SUPX price history - candidate market context.
SUPX short-interest context and borrow context - candidate positioning and indicative borrow.

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	4/5	A non-zero quote conflicts with a fresh Chapter 11 sale and a prepetition deficit, but common recovery is unresolved
Evidence base	5/5	Aug. 27 primary 8-K, June 30 10-Q, and current price and positioning context are cited
Positioning and flows	3/5	Short interest and indicative borrow exist, but broker locate, recall, order-book, and fund-flow evidence is missing
Catalyst path	4/5	DIP, sale, auction, closing, and plan steps are observable, though court dates and outcomes are not fixed
Payoff architecture	3/5	The base decline is large, but the price-only adverse case is much larger and after-cost EV is not computable
Invalidation discipline	4/5	Court recovery, higher bids, operating evidence, claim treatment, and execution failures are explicit
Differentiated insight	4/5	The key distinction is estate consideration versus residual common value, with the DIP roll-up kept separate from new money
Client value	4/5	The claim and catalyst ladder is useful even when no short can be executed

Total: 31/40. Classification: Watchlist. The score cannot override the failed 10/5 adverse bound, unavailable borrow, unresolved claims, and missing execution data.

Bottom Line

BTAI is the strongest fresh U.S. short research candidate because the Chapter 11 filing and Teva sale create a dated, observable test of whether common equity has residual value. The sale consideration is not a common recovery, the DIP roll-up is not new cash, and the June balance sheet gives the short thesis a serious capital-structure basis. The stock's 74.76% collapse and the absence of a verified locate make the expression dangerous. Until the court orders, claims, sale settlement, common denominator, borrow, and exit liquidity are verified, the correct state is Watchlist with no executable entry.

AI Illustration Prompt

Create a realistic editorial illustration for The Mispricing Desk about BioXcel Therapeutics (BTAI): a Delaware bankruptcy courtroom at dawn, viewed across a long physical claims ledger. On the left, a restrained Teva asset-sale folder marked $57.5M upfront with separate translucent tabs for $19M new-money DIP, $58.25M roll-up, and contingent milestones. On the right, a small common-equity certificate sits behind a glass barrier labeled 31.305M June shares, beside a red but understated ENTRY UNVERIFIED stamp. In the center, show a bridge with exact readable figures $0.1814 reference, $144.259M June liabilities, -$115.460M stockholders' deficit, 3.314M shares short, and 0 shares shown available to borrow. Use charcoal, warm paper, faded court-blue, muted amber, and a single restrained red accent; documentary financial-journalism lighting; tactile paper, glass, wood, and brushed metal; no rockets, coins, generic candlestick charts, invented logos, or extra numbers. Make the senior-claim ladder and the incomplete common-recovery path visually clear. Add a subtle readable The Mispricing Desk watermark on the courtroom wall. Wide 16:9 composition, premium magazine art direction, crisp typography, no personalized advice.